FLT3 and acute myeloid leukemia: To shed light on the molecular heterogeneity of AML blasts, we performed targeted NGS on the cell sub-populations of 6 FLT3-ITDmut patients, using the OncomineTM-Myeloid-Research-Assay-panel (Fig. 4).